Literature DB >> 26053118

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Naif Khalaf Alharbi1, Alexandra J Spencer2, Adrian V S Hill2, Sarah C Gilbert2.   

Abstract

Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia virus, which has been used as a recombinant vaccine vector in many vaccine development programmes. The loss of many immunosuppressive and host-range genes resulted in a safe and immunogenic vaccine vector. However it still retains some immunomodulatory genes that may reduce MVA immunogenicity. Earlier reports demonstrated that the deletion of the A41L, B15R, C6L, or C12L open reading frames (ORFs) enhanced cellular immune responses in recombinant MVA (rMVA) by up to 2-fold. However, previously, we showed that deletion of the C12L, A44L, A46R, B7R, or B15R ORFs from rMVA, using MVA-BAC recombineering technology, did not enhance rMVA immunogenicity at either peak or memory cellular immune responses. Here, we extend our previous study to examine the effect of deleting clusters of genes on rMVA cellular immunogenicity. Two clusters of fifteen genes were deleted in one rMVA mutant that encodes either the 85A antigen of Mycobacterium tuberculosis or an immunodominant H2-Kd-restricted murine malaria epitope (pb9). The deletion mutants were tested in prime only or prime and boost vaccination regimens. The responses showed no improved peak or memory CD8+ T cell frequencies. Our results suggest that the reported small increases in MVA deletion mutants could not be replicated with different antigens, or epitopes. Therefore, the gene deletion strategy may not be taken as a generic approach for improving the immunogenicity of MVA-based vaccines, and should be carefully assessed for every individual recombinant antigen.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26053118      PMCID: PMC4459983          DOI: 10.1371/journal.pone.0128626

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  53 in total

1.  Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass.

Authors:  Robert Alcock; Matthew G Cottingham; Christine S Rollier; Julie Furze; Samodh D De Costa; Marian Hanlon; Alexandra J Spencer; Jared D Honeycutt; David H Wyllie; Sarah C Gilbert; Migena Bregu; Adrian V S Hill
Journal:  Sci Transl Med       Date:  2010-02-17       Impact factor: 17.956

2.  Isolation and characterization of protective cytolytic T cells in a rodent malaria model system.

Authors:  P Romero; J L Maryanski; A S Cordey; G Corradin; R S Nussenzweig; F Zavala
Journal:  Immunol Lett       Date:  1990-08       Impact factor: 3.685

3.  The vaccinia virus B9R protein is a 6 kDa intracellular protein that is non-essential for virus replication and virulence.

Authors:  Nicola Price; David C Tscharke; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2002-04       Impact factor: 3.891

Review 4.  Innate immune recognition of poxviral vaccine vectors.

Authors:  Erin L Lousberg; Kerrilyn R Diener; Michael P Brown; John D Hayball
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

5.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Authors:  H Stickl; V Hochstein-Mintzel; A Mayr; H C Huber; H Schäfer; A Holzner
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

6.  A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence.

Authors:  Julian A Symons; David C Tscharke; Nicola Price; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

7.  Vaccinia virus expresses a novel profilin with a higher affinity for polyphosphoinositides than actin.

Authors:  L M Machesky; N B Cole; B Moss; T D Pollard
Journal:  Biochemistry       Date:  1994-09-06       Impact factor: 3.162

8.  Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7.

Authors:  Leonie Unterholzner; Rebecca P Sumner; Marcin Baran; Hongwei Ren; Daniel S Mansur; Nollaig M Bourke; Felix Randow; Geoffrey L Smith; Andrew G Bowie
Journal:  PLoS Pathog       Date:  2011-09-08       Impact factor: 6.823

9.  A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus.

Authors:  Alí Alejo; M Begoña Ruiz-Argüello; Yin Ho; Vincent P Smith; Margarida Saraiva; Antonio Alcami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-31       Impact factor: 12.779

10.  Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein.

Authors:  Samantha Cooray; Mohammad W Bahar; Nicola G A Abrescia; Colin E McVey; Nathan W Bartlett; Ron A-J Chen; David I Stuart; Jonathan M Grimes; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2007-06       Impact factor: 3.891

View more
  6 in total

1.  Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination.

Authors:  Rodrigo Nalio Ramos; Caroline Tosch; Fiorella Kotsias; Marie-Christine Claudepierre; Doris Schmitt; Christelle Remy-Ziller; Chantal Hoffmann; Marine Ricordel; Virginie Nourtier; Isabelle Farine; Laurence Laruelle; Julie Hortelano; Clementine Spring-Giusti; Christine Sedlik; Christophe Le Tourneau; Caroline Hoffmann; Nathalie Silvestre; Philippe Erbs; Kaidre Bendjama; Christine Thioudellet; Eric Quemeneur; Eliane Piaggio; Karola Rittner
Journal:  Clin Transl Immunology       Date:  2022-05-08

Review 2.  Recombinant Ranaviruses for Studying Evolution of Host-Pathogen Interactions in Ectothermic Vertebrates.

Authors:  Jacques Robert; James K Jancovich
Journal:  Viruses       Date:  2016-07-06       Impact factor: 5.048

Review 3.  Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.

Authors:  Jonas D Albarnaz; Alice A Torres; Geoffrey L Smith
Journal:  Viruses       Date:  2018-02-28       Impact factor: 5.048

4.  Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Cristina Sánchez-Corzo; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  Viruses       Date:  2017-12-27       Impact factor: 5.048

5.  Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.

Authors:  Naif Khalaf Alharbi; Fahad Aljamaan; Haya A Aljami; Mohammed W Alenazi; Hind Albalawi; Abdulrahman Almasoud; Fatima J Alharthi; Esam I Azhar; Tlili Barhoumi; Mohammad Bosaeed; Sarah C Gilbert; Anwar M Hashem
Journal:  Vaccines (Basel)       Date:  2022-08-17

6.  Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.

Authors:  María Pía Holgado; Juliana Falivene; Cynthia Maeto; Micaela Amigo; María Fernanda Pascutti; María Belén Vecchione; Andrea Bruttomesso; Gabriela Calamante; María Paula Del Médico-Zajac; María Magdalena Gherardi
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.